US growth ETFs compared: returns and risk
Funds that tilt towards companies with faster expected growth, typically technology and consumer names.
Data updated October 2026
| Fund | 1Y | 3Y a yr | 5Y a yr | 10Y a yr | Volatility | Max drawdown | Since |
|---|---|---|---|---|---|---|---|
 VUGVanguard Growth ETF | +11.7% | +25.0% | +11.8% | — | 21.9% | −35.9% | 2020 |
| SCHGSchwab U.S. Large-Cap Growth ETF | +11.9% | +25.1% | +12.9% | +18.1% | 19.7% | −34.9% | 2010 |
| IWFiShares Russell 1000 Growth ETF | +5.2% | +22.5% | +11.3% | +17.1% | 20.6% | −51.8% | 2006 |
| MGKVanguard Mega Cap Growth ETF | +13.2% | +25.8% | +13.1% | +18.2% | 21.1% | −48.4% | 2007 |
| SPYGSPDR Portfolio S&P 500 Growth ETF | +17.0% | +27.6% | +13.3% | — | 20.9% | −32.7% | 2020 |
Total returns with dividends reinvested, in each fund’s trading currency, to the last close; periods longer than a year are annualised. Volatility and maximum drawdown cover each fund’s whole history since the year shown, so they are comparable only between funds with similar start dates.
Head-to-head comparisons
Other ETF categories
- S&P 500 ETFs
- Total US stock market ETFs
- Nasdaq-100 ETFs
- Dow Jones and equal-weight ETFs
- US small and mid cap ETFs
- US value ETFs
- Small cap value and growth ETFs
- Dividend ETFs
- Covered call and equity income ETFs
- Factor ETFs (min vol, quality, momentum, value)
- World and all-world ETFs
- International developed markets ETFs
- Europe ETFs
- Emerging markets and Asia ETFs
- Technology and semiconductor ETFs
- US sector ETFs
- Real estate (REIT) ETFs
- Thematic ETFs
- US Treasury bond ETFs
- Inflation-linked bond ETFs
- Aggregate bond ETFs
- Corporate, high yield and municipal bond ETFs
- Cash and T-bill ETFs
- Gold and precious metals ETFs
- Oil, gas and commodity ETFs
- Bitcoin and crypto ETFs
- Leveraged and inverse ETFs
- Allocation and multi-asset ETFs
Source: MarketStack end-of-day prices, total return with dividends reinvested. Figures are historical and descriptive; they are not forecasts and not investment advice. MEDGE Capital does not recommend buying or selling any instrument. Risk disclaimer.